Previous close | 2.4000 |
Open | 2.2300 |
Bid | 1.5000 |
Ask | 4.6000 |
Strike | 105.00 |
Expiry date | 2024-05-17 |
Day's range | 2.2300 - 2.2300 |
Contract range | N/A |
Volume | |
Open interest | 1.45k |
AUSTIN, Texas, May 03, 2024--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and tumor-informed molecular residual disease (MRD) test, Signatera, to detect recurrence early in patients with early-stage breast cancer. The full study can be found here.
On April 29, 2024, Michael Brophy, the Chief Financial Officer of Natera Inc (NASDAQ:NTRA), sold 1,238 shares of the company.
On April 29, 2024, Steven Chapman, CEO and President of Natera Inc (NASDAQ:NTRA), sold 4,084 shares of the company.